0 Комментарии
0 Поделились
1Кб Просмотры
0 предпросмотр
Поиск
Знакомьтесь и заводите новых друзей
-
Войдите, чтобы отмечать, делиться и комментировать!
-
How Digital Technologies Are Transforming Clinical Trial Efficiency and ComplianceFor decades, traditional clinical trials have been hampered by high operational friction: slow patient recruitment, heavy administrative site burdens, static paper-based records, and data reconciliation bottlenecks. Today, the life sciences industry is experiencing a decisive shift. Digital technologies have moved past the initial experimentation phase, transforming into core infrastructure...0 Комментарии 0 Поделились 2Кб Просмотры 0 предпросмотр
-
Key Highlights of the NDCT Amendment Rules 2026: Transforming India’s Clinical Research LandscapeThe clinical research and pharmaceutical sectors in India are undergoing a profound evolution. To streamline drug development, eliminate procedural bottlenecks, and align national standards with global frameworks, the Ministry of Health and Family Welfare (MoHFW) and the Central Drugs Standard Control Organization (CDSCO) introduced the landmark New Drugs and Clinical Trials (NDCT) Amendment...0 Комментарии 0 Поделились 2Кб Просмотры 0 предпросмотр
-
Mastering PK-Stat Reviews in Bioequivalence Studies: Bridging Data and Regulatory SuccessIn the rigorous world of pharmaceutical development, proving that a generic or alternative formulation matches a brand-name reference product requires far more than just laboratory similarity. It demands undeniable mathematical and statistical proof. At the heart of this process lies the Pharmacokinetic-Statistical (PK-Stat) Review—the critical link that translates raw plasma...0 Комментарии 0 Поделились 2Кб Просмотры 0 предпросмотр
-
Mastering Sponsor Oversight in Clinical Trials: Ensuring Quality and ComplianceIn modern clinical research, outsourcing operational tasks to Contract Research Organizations (CROs), vendors, and central laboratories is standard practice. However, there is one critical responsibility that a pharmaceutical or biotech sponsor can never outsource: sponsor oversight. Regulatory authorities worldwide—including the US FDA, EMA, and CDSCO—make it explicitly clear that...0 Комментарии 0 Поделились 2Кб Просмотры 0 предпросмотр